AG
XLO icon

Artal Group’s Xilio Therapeutics XLO Stock Holding History

Artal Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-32,143
Closed -$248K – 125
2023
Q4 		$248K Hold
32,143
– – 0.01% 91
2023
Q3 		$950K Hold
32,143
– – 0.04% 78
2023
Q2 		$1.18M Hold
32,143
– – 0.04% 87
2023
Q1 		$1.43M Hold
32,143
– – 0.08% 86
2022
Q4 		$1.21M Hold
32,143
– – 0.07% 101
2022
Q3 		$1.31M Hold
32,143
– – 0.06% 103
2022
Q2 		$1.31M Hold
32,143
– – 0.07% 111
2022
Q1 		$3.18M Hold
32,143
– – 0.13% 100
2021
Q4 		$7.2M Buy
+32,143
New +$7.66M 0.2% 85

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artal Group's XLO Position: Q1 2024 in Review

Artal Group sold out of Xilio Therapeutics (XLO) in Q1 2024, closing a stake of 32,143 shares — an estimated $248K sold.

Artal Group first reported a position in XLO in Q4 2021 and held it in 9 quarters. The position peaked at $7.2M in Q4 2021. 30 funds tracked by Wall St. Rank hold XLO as of Q1 2024.

  • Artal Group reported no remaining Xilio Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Artal Group sold 32,143 Xilio Therapeutics shares in Q1 2024, an estimated $248K.
  • Artal Group first reported a position in Xilio Therapeutics in Q4 2021 and held it in 9 quarters.
  • Artal Group's Xilio Therapeutics position peaked at $7.2M in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2024.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.